Company Description
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF).
It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trial.
The company was formerly known as Sling Therapeutics, Inc. and changed its name to Sionna Therapeutics, Inc. in July 2021.
Sionna Therapeutics, Inc. was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
| Country | United States |
| Founded | 2019 |
| IPO Date | Feb 7, 2025 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 59 |
| CEO | Michael Cloonan |
Contact Details
Address: 21 Hickory Drive, Suite 500 Waltham, Massachusetts 02451 United States | |
| Phone | 617 819 2020 |
| Website | sionnatx.com |
Stock Details
| Ticker Symbol | SION |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $18.00 |
| CIK Code | 0002036042 |
| CUSIP Number | 829401108 |
| ISIN Number | US8294011080 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Michael Cloonan M.B.A. | President, Chief Executive Officer and Director |
| Elena H. Ridloff C.F.A. | Chief Financial Officer |
| Dr. Charlotte McKee M.D. | Chief Medical Officer |
| Dr. Greg Hurlbut Ph.D. | Co-Founder and Senior Vice President of Discovery Research |
| Dr. Mark Munson Ph.D. | Co-founder and Senior Vice President of Medicinal Chemistry |
| Meghan Bagshaw | Vice President of Programs, Portfolio and Operations |
| Andy Chu | Vice President of Information and Technology |
| Jennifer Fitzpatrick J.D. | Chief Legal Officer |
| Vanya Sagar | Chief People Officer |
| Mara Furlow M.S. | Senior Vice President of Global Regulatory Affairs and Quality |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 27, 2026 | ARS | Filing |
| Apr 27, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 27, 2026 | DEF 14A | Other definitive proxy statements |
| Apr 20, 2026 | SCHEDULE 13D/A | Filing |
| Mar 5, 2026 | 144 | Filing |
| Mar 2, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 2, 2026 | S-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers |
| Mar 2, 2026 | 10-K | Annual Report |
| Mar 2, 2026 | 8-K | Current Report |
| Jan 22, 2026 | 144 | Filing |